Big update
13 May 2026
Quarterly financial report filed for Q1 2026
Shows how the company performed financially in the first three months of 2026.
SEC 10-Q · filed 2026-05-13
View filing ↗
What's happening at Zenas BioPharma, Inc.
Zenas BioPharma, Inc.'s latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026
People
13 May 2026
Director Tomas Kiselak steps down from board
Board leadership changes can affect company decisions and direction.
SEC 8-K · filed 2026-05-13
View filing ↗
Money
31 Mar 2026
Raises $200 million with convertible notes due 2032
Money raised helps fund drug development; notes can convert to stock at $26.48 per share.
SEC 8-K · filed 2026-03-31
View filing ↗
Money
30 Mar 2026
SEC filing for $200 million convertible notes offering
Official prospectus details the terms investors need before buying the convertible notes.
SEC 424B5 · filed 2026-03-30
View filing ↗
Money
30 Mar 2026
Offers 5 million shares of common stock publicly
Selling stock dilutes existing shareholders but raises cash for company operations.
SEC 424B5 · filed 2026-03-30
View filing ↗
Money
26 Mar 2026
Preliminary prospectus for convertible notes offering
Early draft of terms for $200 million debt offering that can convert to stock.
SEC 424B5 · filed 2026-03-26
View filing ↗
Money
26 Mar 2026
Preliminary prospectus for 5 million share stock offering
Early draft of terms for public stock sale at $22.19 per share on March 25, 2026.
SEC 424B5 · filed 2026-03-26
View filing ↗
Common questions
How does Stocky track Zenas BioPharma, Inc.'s company events?
Stocky reads Zenas BioPharma, Inc.'s official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
What was Zenas BioPharma, Inc.'s most recent SEC filing?
Zenas BioPharma, Inc.'s most recent tracked filing was a 10-Q on 13 May 2026: Quarterly financial report filed for Q1 2026.
Is this financial advice?
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.